Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes

Margarite D. Matossian; Steven Elliott; Van T. Hoang; Hope E. Burks; Theresa B. Phamduy; Douglas B. Chrisey; William J. Zuercher; David H. Drewry; Carrow Wells; Bridgette Collins-Burow; Matthew E. Burow

doi:10.1371/journal.pone.0177802

Loading metrics

Open Access

Peer-reviewed

Research Article

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes

Margarite D. Matossian,

Affiliation Department of Medicine: Section of Hematology and Oncology, Tulane University, New Orleans, Louisiana, United States of America

http://orcid.org/0000-0002-9527-1043

⨯
Steven Elliott ,

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Department of Medicine: Section of Hematology and Oncology, Tulane University, New Orleans, Louisiana, United States of America
⨯
Van T. Hoang ,

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Department of Medicine: Section of Hematology and Oncology, Tulane University, New Orleans, Louisiana, United States of America
⨯
Hope E. Burks ,

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Department of Medicine: Section of Hematology and Oncology, Tulane University, New Orleans, Louisiana, United States of America
⨯
Theresa B. Phamduy ,

¶‡ These authors also contributed equally to this work.

Affiliation Department of Physics, Tulane University, New Orleans, Louisiana, United States of America
⨯
Douglas B. Chrisey ,

¶‡ These authors also contributed equally to this work.

Affiliation Department of Physics, Tulane University, New Orleans, Louisiana, United States of America
⨯
William J. Zuercher ,

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Eshelman School of Pharmacy, University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States of America
⨯
David H. Drewry ,

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Eshelman School of Pharmacy, University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States of America
⨯
Carrow Wells ,

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Eshelman School of Pharmacy, University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States of America
⨯
Bridgette Collins-Burow ,

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Department of Medicine: Section of Hematology and Oncology, Tulane University, New Orleans, Louisiana, United States of America
⨯
Matthew E. Burow

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

* E-mail: mburow@tulane.edu

Affiliation Department of Medicine: Section of Hematology and Oncology, Tulane University, New Orleans, Louisiana, United States of America
⨯

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes

Margarite D. Matossian,
Steven Elliott,
Van T. Hoang,
Hope E. Burks,
Theresa B. Phamduy,
Douglas B. Chrisey,
William J. Zuercher,
David H. Drewry,
Carrow Wells,
Bridgette Collins-Burow

Published: August 3, 2017
https://doi.org/10.1371/journal.pone.0177802

About the Authors

Margarite D. Matossian

Affiliation Department of Medicine: Section of Hematology and Oncology, Tulane University, New Orleans, Louisiana, United States of America

http://orcid.org/0000-0002-9527-1043

Steven Elliott

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Department of Medicine: Section of Hematology and Oncology, Tulane University, New Orleans, Louisiana, United States of America

Van T. Hoang

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Department of Medicine: Section of Hematology and Oncology, Tulane University, New Orleans, Louisiana, United States of America

Hope E. Burks

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Department of Medicine: Section of Hematology and Oncology, Tulane University, New Orleans, Louisiana, United States of America

Theresa B. Phamduy

¶‡ These authors also contributed equally to this work.

Affiliation Department of Physics, Tulane University, New Orleans, Louisiana, United States of America

Douglas B. Chrisey

¶‡ These authors also contributed equally to this work.

Affiliation Department of Physics, Tulane University, New Orleans, Louisiana, United States of America

William J. Zuercher

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Eshelman School of Pharmacy, University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States of America

David H. Drewry

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Eshelman School of Pharmacy, University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States of America

Carrow Wells

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Eshelman School of Pharmacy, University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States of America

Bridgette Collins-Burow

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

Affiliation Department of Medicine: Section of Hematology and Oncology, Tulane University, New Orleans, Louisiana, United States of America

Matthew E. Burow

Contributed equally to this work with: Steven Elliott, Van T. Hoang, Hope E. Burks, William J. Zuercher, David H. Drewry, Carrow Wells, Bridgette Collins-Burow, Matthew E. Burow

* E-mail: mburow@tulane.edu

Affiliation Department of Medicine: Section of Hematology and Oncology, Tulane University, New Orleans, Louisiana, United States of America

Competing Interests

We would like to thank GlaxoSmithKline for the generous donation of PKIS and PKIS2 compounds for these studies. David H. Drewry, Carrow Wells, and William J. Zuercher are members of the Structural Genomics Consortium (SGC). The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA), Janssen, Merck & Co., Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome Trust. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceptualization: MEB BC-B SE WJZ DHD CW MDM. Data curation: SE MDM CW VTH HEB TBP WJZ DHD. Formal analysis: MDM CW VTH HEB WJZ DHD. Funding acquisition: MEB BC-B. Investigation: SE MDM CW VTH HEB TBP WJZ DHD. Methodology: MEB SE WJZ DHD MDM CW. Project administration: MEB SE MDM WJZ DHD CW. Resources: MEB BC-B WJZ DHD TBP DBC. Software: TBP MDM. Supervision: MEB DHD WJZ SE. Validation: SE MDM VTH HEB CW MEB WJZ DHD. Visualization: MDM CW DHD WJZ SE MEB. Writing – original draft: MDM. Writing – review & editing: MDM MEB WJZ DHD CW SE VTH HEB.

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Phenotypes
Is the Subject Area "Phenotypes" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Gene expression
Is the Subject Area "Gene expression" applicable to this article?

Thanks for your feedback.
Library screening
Is the Subject Area "Library screening" applicable to this article?

Thanks for your feedback.
Small molecules
Is the Subject Area "Small molecules" applicable to this article?

Thanks for your feedback.
Cell migration
Is the Subject Area "Cell migration" applicable to this article?

Thanks for your feedback.
Kinase inhibitors
Is the Subject Area "Kinase inhibitors" applicable to this article?

Thanks for your feedback.